Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis

Abstract

PPI use in decompensated cirrhosis is associated with increased risk of mortality and hepatic decompensation. Longer PPI exposure with cDDD > 90 increases the risk of mortality.